Revisiting the Significance of Warfarin Protein-Binding Displacement Interactions

@article{Sands2002RevisitingTS,
  title={Revisiting the Significance of Warfarin Protein-Binding Displacement Interactions},
  author={Charles D. Sands and Edwina S Chan and Timothy E. Welty},
  journal={Annals of Pharmacotherapy},
  year={2002},
  volume={36},
  pages={1642 - 1644}
}
Most clinicians who manage patients on warfarin therapy are aware of the transient nature of changes in the prothrombin time (PT) secondary to protein-binding displacement interactions. However, anecdotal case reports and clinical impressions by some healthcare professionals continue to inflate, on occasion, the importance of warfarin protein-binding displacement interactions,1 despite the fact that the transient nature of the interaction has been well described for >30 years.2-7 Thus, it is… 

Topics from this paper

A Potential Interaction between Warfarin and Atovaquone
TLDR
Although current medication references do not report an interaction between atovaquone and warfarin, knowledge of their pharmacodynamic properties can enable practitioners to anticipate the consequences of a possible transient increase in warFarin serum concentration, such as that seen in this patient.
Unusual hypersensitivity to warfarin in a critically ill patient
TLDR
It should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage.
Towards optimal dosing of coumarin derivatives: the role of pharmacogenetics
TLDR
This thesis describes studies that aimed to develop pretreatment personalized dosing strategies for coumarins and discusses the most promising findings, which are the decreased acenocoumarol, but not phenprocoumon, dose requirements for patients who use concurrently atorvastatin, simvastsatin, pravastatin or rosuvASTatin.
Drug Interaction and Pharmacist
  • J. Ansari
  • Medicine
    Journal of young pharmacists : JYP
  • 2010
TLDR
The pharmacist, along with the prescriber, has a duty to ensure that patients are aware of the risk of side effects and a suitable course of action should they occur.
Probable Interaction Between Warfarin and Divalproex Sodium
  • Sarah L. Anderson, J. Marrs
  • Medicine
    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
  • 2014
TLDR
Patients receiving concurrent warfarin and divalproex sodium therapy should be monitored closely for changes in INR values as the combination may increase the INR and put the patient at increased risk for bleeding.
Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics
TLDR
The study results demonstrate that nilotinib has no effect on single-dose warfarin pharmacokinetics and pharmacodynamics, which implies thatnilotinib is unlikely to inhibit CYP2C9 activity in human subjects, and suggest that warFarin and nilotinIB may be used concurrently as needed.
The Potential Drug-Drug Interaction between Warfarin and Glibenclamide in Diabetic and Hypercoagulable Rats Model
  • S. Salim
  • Bulletin of Pharmaceutical Sciences. Assiut
  • 2021
Diabetic patients are vulnerable to many vascular events. So, diabetic patients treated with oral antidiabetic glibenclamide, may be also treated with oral anticoagulant warfarin, for prophylaxis and
Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy.
TLDR
A case of an inadvertent increase in the international normalized ratio (INR) after the addition of bismuth subsalicylate for the treatment of diarrhea in an enterally fed patient receiving warfarin therapy, which yielded scores consistent with a probable adverse drug interaction.
Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area
TLDR
Inter-individual variability in the response to warfarin therapy, which cut across racial classifications is found, confirms the possible influence of concomitant morbidity on patient response to anticoagulant therapy and assesses the quality of management ofwarfarin treatment in a local primary-care setting.
Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats
TLDR
The effect of ETV is evaluated on the pharmacokinetics and blood clotting time of racemic warfarin in rats to prevent HIV‐related thromboembolic events.
...
1
2
3
...

References

SHOWING 1-10 OF 30 REFERENCES
KINETICS AND CLINICAL IMPORTANCE OF DISPLACEMENT OF WARFARIN FROM ALBUMIN BY ACIDIC DRUGS *
TLDR
Identification of drugs that displace warfarin from albumin and could thereby potentiate its hypoprothrombinemic action can be identified by controlled experiments in volunteers and through prospective monitoring of hospitalized anticoagulated patients.
Adverse Interactions Between Warfarin and Nonsteroidal Antiinflammatory Drugs: Mechanisms, Clinical Significance, and Avoidance
  • T. Chan
  • Medicine
    The Annals of pharmacotherapy
  • 1995
TLDR
The combined use of warfarin and NSAIDs is generally discouraged because of the increased risk of bleeding in patients who also require NSAIDs, phenylbutazone and its analogs, high-dose aspirin, mefenamic acid, excessive use of topical methyl salicylate, andNSAIDs that are associated with a higherrisk of bleeding peptic ulcers should be avoided.
Protein Binding Drug Displacement Interactions
  • J. MacKichan
  • Chemistry, Medicine
    Clinical pharmacokinetics
  • 1989
TLDR
It is concluded that although drug displacement is common and sometimes predictable, it alone is rarely responsible for observations of adverse drug interactions.
The warfarin‐sulfinpyrazone interaction: stereochemical considerations
TLDR
Pharmacokinetic analysis of the data suggests that at least four distinct enzymes (two oxidases and two reductases) are involved in the metabolism of warfarin.
Interaction between diflunisal and warfarin
TLDR
Diflunisal reduced both the maximum plasma protein‐binding capacity for warfarin and the apparent association constant and there was a correlation between plasma diflunaisal and percentage unbound warFarin.
Implications of Cytochrome P450 2C9 Polymorphism on Warfarin Metabolism and Dosing
TLDR
Adverse outcomes associated with warfarin possibly could be avoided by identifying patients with variant alleles before therapy and starting therapy at low dosages.
Warfarin and Celecoxib Interaction
TLDR
Patients receiving warfarin should be carefully monitored when adding, changing, or removing celecoxib from their medication regimen, as it is possible that other drug therapies or disease states may have contributed to the elevation in INR.
Celecoxib Does Not Significantly Alter the Pharmacokinetics or Hypoprothrombinemic Effect of Warfarin in Healthy Subjects
TLDR
Concomitant administration of celecoxib has no significant effect on PT or steady‐state pharmacokinetics of S‐ or R‐warfarin in healthy volunteers.
Pharmacokinetic Consequences of Drug Displacement from Blood and Tissue Proteins
TLDR
Although total drug concentrations in blood will be unchanged, free drug concentrations will be increased and drug response enhanced for non-restrictively cleared drugs as a result of displacement from blood protein, possibly necessitating a dosage reduction.
Potential Interaction between Celecoxib and Warfarin
TLDR
Although celecoxib did not appear to alter the pharm acokinetics of Ror S-warfarin in volunteers, it may cause an interaction in elderly patients, and the importance of close monitoring of patients receiving these drugs concomitantly is emphasized.
...
1
2
3
...